Combined Therapy for Depression and Insomnia in Adults
Tests combined insomnia and depression behavioral therapies in adults with both conditions.
Plain-language title generated from the registry record
Registry title: Combined Effect of TCC-I and BATD on Depressive Symptoms and Insomnia
Key facts
- Where
- Liège, BelgiumSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with depression and insomnia who understand French well. It tests two talk-based programs given together.
- Age
- 18 Years to 67 Years
- Sex
- All sexes can join.
- Disease stage
- Moderate depression (PhQ 9 above 10) and insomnia (Insomnia Severity Index above 11), meeting DSM-V criteria for both.
- Earlier treatment
- People cannot be receiving other treatment for sleep or depression, or other psychological treatment. Antidepressants and anxiolytics are accepted if stable for at least two months with no planned changes in the following weeks.
Main reasons for not taking part
- Symptoms suggesting psychotic disorder, bipolar disorder or substance abuse disorder
- Excessive suicidal ideation
- Another sleep problem such as sleep apnea, restless legs syndrome, narcolepsy, sleepwalking or periodic limb movements
- Other treatment for sleep or depression, or parallel psychological or drug treatment
- No longer working, or working night shifts
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 67 years old?
Source: NCT06633263, who can take part
Where in Belgium
- CPLU (clinique psychologique et logopédique de l université de Liège)Liège, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Liege
- Trial code
- NCT06633263
- Record updated
- 1 November 2024
- Original description
The goals of this interventional study is to study if the combine effects of Behavioral Activation Treatment for Depression (BATD) and Cognitive Behavioral Therapy for Insomnia (CBT-I) is effective on primary outcomes : depression, insomnia, well-being and anxiety and secondary outcomes : worry, rumination, behavioral inertia, experiential avoidance, anticipatory pleasure deficits, cognitive resource deficits, emotional reactivity, quality of sleep, and sleep beliefs for participants suffering from depression and insomnia disorders.Read full original descriptionShow less
Combined Effect of Cognitive Behavioral Therapy for Insomnia and a Behavioral Activation Program for Depression on Depressive Symptoms and Insomnia : A Multiple Case Study
The goals of this interventional study is to study if the combine effects of Behavioral Activation Treatment for Depression (BATD) and Cognitive Behavioral Therapy for Insomnia (CBT-I) is effective on primary outcomes : depression, insomnia, well-being and anxiety and secondary outcomes : worry, rumination, behavioral inertia, experiential avoidance, anticipatory pleasure deficits, cognitive resource deficits, emotional reactivity, quality of sleep, and sleep beliefs for participants suffering from depression and insomnia disorders.
Inclusion: Participants will be adults with depression (PhQ 9 \> 10; cut-off for moderate depression) and insomnia (Insomnia Severity Index \> 11) who also meet DSM-V criteria for depression and insomnia (APA, 2013) and have a good understanding of French.
Exclusion: Participants who have recently received or are currently receiving other interventions that could be confused with our intervention, such as those undergoing treatment for sleep or depression, or those undergoing parallel psychological or pharmacological treatment (antidepressants and anxiolytics will be accepted provided they have been stabilized for at least two months and there are no planned changes in the following weeks); Participants requiring different treatment, i.e. those with symptoms suggestive of psychotic disorder, bipolar disorder, substance abuse disorder, excessive suicidal ideation, or other sleep pathology (such as sleep apnea, restless legs syndrome, narcolepsy, sleepwalking, or periodic limb movements); Participants with commitments that disrupt nocturnal sleep cycles and habits, such as those who no longer work or who work night shifts, will also be excluded from the study.